Clinical-stage potential Target brain cancer patients underserved by standard therapies, presenting a high-need market with potential for clinical adoption discussions, partnerships, and co-development opportunities around ulRFE technology.

Non-invasive offering EMulate’s non-invasive ulRFE device could appeal to hospitals and clinics seeking safer, non-chemical cancer treatments, enabling sales conversations around integration with existing neuro-oncology workflows and reduced side effects.

Strategic partnerships Board additions and governance updates indicate active investor and advisor engagement; leverage this for collaborations with academic medical centers, KOLs, and potential licensing or co-development deals to expand indication reach.

Financial runway With tens of millions in revenue and a modest funding base, pursue partnerships and grant-driven programs to accelerate clinical validation, expand regulatory pathways, and de-risk commercialization activities.

Expansion opportunities Pre-clinical work in oncology and pain suggests future markets beyond brain cancer; explore cross-indication sales in oncology or pain management, plus veterinary and other non-medical applications to broaden customer segments.